Testosterone suppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction

Wang,Xiao-Fei; Qu,Xing-Qian; Zhang,Tian-Tian; Zhang,Jun-Feng

doi:10.3892/etm.2015.2269

Testosterone suppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction

Authors:
- Xiao-Fei Wang
- Xing-Qian Qu
- Tian-Tian Zhang
- Jun-Feng Zhang
View Affiliations

Affiliations: Department of Cardiology, Third People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, P.R. China, Department of Anesthesiology, Third People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, P.R. China
Published online on: February 6, 2015 https://doi.org/10.3892/etm.2015.2269
Pages: 1283-1291

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Men with congestive heart failure (CHF) have relatively low testosterone levels. Several studies demonstrated that testosterone treatment increases cardiac output and reduces peripheral vascular resistance. However, the effects of testosterone on heart function, cardiomyocyte apoptosis and ventricular remodeling have not been fully elucidated. This study was conducted to investigate the effects of testosterone on heart function, cardiomyocyte apoptosis and ventricular remodeling in male rats post‑myocardial infarction. A total of 86 male rats were randomly assigned to undergo ligation of the coronary artery (n=70) or pseudosurgery (n=16). After 6 weeks, a left ventricular ejection fraction (LVEF) of ≤45% was defined as a successful model of CHF. the model rats were randomly assigned to 3 groups, namely low‑dose testosterone (TU), high‑dose TU and placebo (PL) groups. After treatment for 12 weeks, the expression of several mRNA transcripts in myocardial tissue was measured by quantitative polymerase chain reaction. Immunofluorescence was used to measure myocardial caspase‑3 expression. Compared to the PL group, LVEF was significantly improved in the TU treatment groups. Moreover, the mRNA expression of atrial natriuretic peptide, brain natriuretic peptide, matrix metalloproteinase‑2 and sarcoendoplasmic reticulum Ca2+‑ATPase 2a was significantly reduced, while the mRNA expression of glycogen synthase kinase 3β and tissue inhibitor of metalloproteinase‑2 was markedly increased in the TU groups. TU treatment also significantly reduced caspase‑3 expression. Therefore, different doses of TU suppressed ventricular remodeling and improved left ventricular function, reduced apoptosis and prevented mortality in a CHF rat model.

View Figures

View References

1	Holland DJ, Kumbhani DJ, Ahmed SH and Marwick TH: Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 57:1676–1686. 2011. View Article : Google Scholar : PubMed/NCBI
2	Frank KF, Bölck B, Erdmann E and Schwinger RH: Sarcoplasmic reticulum Ca²⁺-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res. 57:20–27. 2003. View Article : Google Scholar
3	Chen Y, Escoubet B, Prunier F, Amour J, Simonides WS, Vivien B, Lenoir C, Heimburger M, Choqueux C, Gellen B, Riou B, Michel JB, Franz WM and Mercadier JJ: Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation. 109:1898–1903. 2004. View Article : Google Scholar : PubMed/NCBI
4	Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P and Lee RT: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 106:55–62. 2000. View Article : Google Scholar : PubMed/NCBI
5	Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS and Jones TH: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profilesin hypogonadal men. J Clin Endocrinol Metab. 89:3313–3318. 2004. View Article : Google Scholar : PubMed/NCBI
6	Pugh PJ, English KM, Jones TH and Channer KS: Testosterone: a natural tonic for the failing heart? QJM. 93:689–694. 2000. View Article : Google Scholar : PubMed/NCBI
7	Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH and Channer KS: Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 27:57–64. 2006. View Article : Google Scholar
8	Pugh PJ, Jones TH and Channer KS: Acute haemodynamic effects of testosteronein men with chronic heart failure. Eur Heart J. 24:909–915. 2003. View Article : Google Scholar : PubMed/NCBI
9	Pugh PJ, Jones RD, West JN, Jones TH and Channer KS: Testosterone treatment for men with chronic heart failure. Heart. 90:446–447. 2004. View Article : Google Scholar : PubMed/NCBI
10	Zhang YZ, Xing XW, He B and Wang LX: Effects of testosterone on cytokines and left ventricular remodeling following heart failure. Cell Physiol Biochem. 20:847–852. 2007. View Article : Google Scholar : PubMed/NCBI
11	Noirhomme P, Jacquet L, Underwood M, EI Khoury G, Goenen M and Dion R: The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cadiothorac Surg. 16:63–67. 1999. View Article : Google Scholar
12	Nahrendorf M, Frantz S, Hu K, von zur Mühlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B and Callies F: Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res. 57:370–378. 2003. View Article : Google Scholar : PubMed/NCBI
13	Jankowska EA, Biel B, Majda J, et al: Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 114:1829–1837. 2006. View Article : Google Scholar : PubMed/NCBI
14	Cleland JG, Khand A and Clark A: The heart failure epidemic: exactly how big is it? Eur Heart J. 22:623–626. 2001. View Article : Google Scholar : PubMed/NCBI
15	Cavallero S, González GE, Puyó AM, Rosón MI, Pérez S, Morales C, Hertig CM, Gelpi RJ and Fernández BE: Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy. J Hypertens. 25:1940–1950. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sanbe A, Gulick J, Han ks MC, Liang Q, Osinska H and Robbins J: Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 92:609–616. 2003. View Article : Google Scholar : PubMed/NCBI
17	Rubio M, Bodi I, Fuller-Bicer GA, Hahn HS, Periasamy M and Schwartz A: Sarcoplasmic reticulum adenosine triphosphatase overexpression in the L-type Ca²⁺ channel mouse results in cardiomyopathy and Ca²⁺-induced arrhythmogenesis. J Cardiovasc Pharmacol Ther. 10:235–249. 2005. View Article : Google Scholar : PubMed/NCBI
18	Pelzer T, Schumann M, Neumann M, deJager T, Stimpel M, Serfling E and Neyses L: 17beta-estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun. 268:192–200. 2000. View Article : Google Scholar : PubMed/NCBI
19	Mocanu MM, Baxter GF and Yellon DM: Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 130:197–200. 2000. View Article : Google Scholar : PubMed/NCBI
20	Perrin C, Ecarnot-Laubriet A, Vergely C and Rochette L: Calpain and caspase-3 inhibitors reduce infarct size and post-ischemie apoptosis in rat heart without modifying contractile recovery. Cell Mol Biol (Noisy-le-grand). 49:Online Pub. OL497–OL505. 2003.